Navigation Links
NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones

ANN ARBOR, Mich., March 6 /PRNewswire/ -- NanoBio(R) Corporation has received its third $10 million tranche of equity funding from Perseus LLC, after having successfully met three critical development milestones: validating the efficacy and safety of its two topical treatments for skin infections and demonstrating the strength of its influenza vaccine in ferret studies.

The company, a spin-off from the University of Michigan, has received a total of $30 million over the past 18 months from Perseus LLC, a leading private equity management firm. The funding has enabled NanoBio to conduct phase 2 clinical trials on its two lead products, topical lotions NB-001 for herpes labialis (cold sores) and NB-002 for onychomycosis (nail fungus). Additionally, the funding has supported extensive animal studies supporting the company's nasal vaccines against influenza, hepatitis B and several additional pathogens.

Preliminary analyses of the data demonstrate the lotions have potent antiviral and antifungal effects without safety concerns or systemic absorption, according to NanoBio scientists.

Phase 2a and Phase 2b clinical trials on NB-001 are complete, while phase 2 clinical trials on NB-002 are in progress and will be completed by the first quarter of 2009. Final data will be presented after the data have undergone peer review processes.

"We're delighted by the considerable progress NanoBio has achieved in all dimensions, most notably its efficacy and safety data in the clinical realm," said Norman C. Selby, senior managing director at Perseus. "We are also pleased that the company has built a sound business infrastructure and a robust research program in the vaccine arena.

"The company's platform technology is proving to be highly effective in combating a broad range of viruses, bacteria and fungi, and we're eagerly anticipating the next round of data on its vaccine studies," he added.

Based on the positive data, NanoBio will move immediately to plan phase 3 testing of NB-001, said James R. Baker Jr., M.D., founder and chairman of NanoBio Corporation.

About NanoBio

NanoBio Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.

SOURCE NanoBio Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment
2. CEL-SCI Corporation Reports First Quarter Financial Results
3. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
4. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
5. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
8. CEL-SCI Corporation Announces 2007 Financial Results
9. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. Immunosyn Corporation Releases SF-1019 Study Results
Post Your Comments:
(Date:12/1/2015)... Germany , December 1, 2015 ... manufacturer of eye and gaze tracking solutions, today announced ... eye trackers as a component of its revolutionary new ... sight, and medical and performance issues in patients. The ... SMI,s mass-market-ready eye tracking platform, which is ready to ...
(Date:12/1/2015)... -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced ... 2016 as the ex-distribution date for Ampio,s previously announced ... Stock of Aytu BioScience, Inc. As announced, Ampio will ... every five (5) shares of Ampio Common Stock owned ... date will be January 4, 2016. ...
(Date:12/1/2015)... , Dec. 1, 2015 Research and ... of the "2016 Global Enteric Disease Testing ... Salmonella, Shigella, Vibrio, Yersinia--France, Germany, Italy, Japan, Spain, ... Japan . --> ... The report is based on a combination ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has won ... order will be from the China Disabled Persons’ Federation, a central government association, for ... for children and adults suffering from severe and profound hearing loss . The ...
(Date:12/1/2015)... Charlotte, NC (PRWEB) , ... December 01, 2015 ... ... NHS Foundation Trust on receiving the 2015 HSJ Acute Sector Innovation Award on ... of improving the patient care experience, and propose exciting enhancements to the medical ...
(Date:11/30/2015)... ... November 30, 2015 , ... Third Molar ... that it has officially launched a sleek, mobile-ready and user-centric redesigned website. , ... new website clearly outlines the benefits that its SEO services provide to dentists ...
(Date:11/30/2015)... NC (PRWEB) , ... November 30, 2015 , ... Trevor ... corporate support as they play for the chance to represent the United States. This ... the opportunity to be a part of their journey in addition to offering corporate ...
(Date:11/30/2015)... Garden City, NY (PRWEB) , ... December 01, ... ... (NAPW) honors Christina Colon as a 2015-2016 inductee into its ... for leadership in pharmacy. NAPW is the nation’s leading networking organization exclusively for ...
Breaking Medicine News(10 mins):